Objective: The positive short-term effects of postmenopausal hormone replacement therapy (HRT) on serum lipids are well known, but it has been suggested that they vanish with time. Cholecalciferol (vitamin D 3 ) is widely used to prevent postmenopausal osteoporosis but the influence of vitamin D 3 on serum lipids is poorly known. The long-term effects of HRT and vitamin D 3 on the concentrations of serum lipids were studied in a population-based prospective 3-year study. Design and methods: 464 women were randomized into four treatment groups: (i) HRT (sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate), (ii) Vit D 3 (vitamin D 3 300 IU/ day), (iii) HRT+Vit D 3 (both as above), (iv) placebo (calcium lactate 500 mg/day). Results: 320 women completed the study. After three years of treatment, serum concentrations of low density lipoprotein (LDL) cholesterol decreased in the HRT group (10.1%, P<0.001) and the HRT+Vit D 3 group (5.9%, P=0.005), increased in the Vit D 3 group (4.1%, P=0.035) but remained unchanged in the placebo group. The concentrations of total cholesterol decreased by 5.8% in the HRT group (P<0.001) and by 3.3% in the HRT+Vit D 3 group (P=0.023), but did not change in the other two groups. Serum concentrations of high density lipoprotein (HDL) cholesterol decreased in the Vit D 3 group (5.2%, P=0.001), HRT+Vit D 3 group (3.7%, P=0.046), and the placebo group (4.5%, P=0.006) but did not change significantly in the HRT group. The HDL/LDL ratio increased in the HRT group (10.5%, P=0.006) and decreased in the Vit D 3 group (10.5%, P<0.001) whereas no changes occurred in the other two groups. In addition, serum triglycerides increased similarly in all groups (14.0-18.8%, P<0.05-0.001). Conclusions: Our results confirm the positive long-term effect of HRT with sequential estradiol valerate and cyproterone acetate on serum lipid concentrations. In addition, the results suggest that vitamin D 3 supplementation may have unfavorable effects on lipids in postmenopausal women. Pure vitamin D 3 treatment was associated with increased serum LDL cholesterol. Furthermore, the beneficial effects of HRT on serum LDL cholesterol content were reduced when estradiol valerate was combined with vitamin D 3 . However, the relevance of these associations to cardiovascular morbidity remains to be established. [495][496][497][498][499][500][501][502] 
Introduction
Physiological postmenopausal changes in serum lipid profiles are associated with an increased risk of coronary heart disease (CHD). According to several authors, postmenopausal hormone replacement therapy (HRT) is beneficial as regards serum lipids (1) (2) (3) . Estrogen may also reduce the risk of CHD through other mechanisms, such as beneficial hemodynamic and hemostatic effects (4, 5) , and the positive influence of carbohydrate metabolism (6, 7) .
Unopposed estrogen therapy may reduce the risk of CHD by about 40-50% (7, 8) . Elevated serum total cholesterol (Chol) and low density lipoprotein cholesterol (LDL-Chol) are both well known risk factors as regards CHD, whereas elevated concentrations of high density lipoprotein cholesterol (HDL-Chol) appear to protect against CHD. The concentrations of HDL-Chol increase by 10-20% and those of LDL-Chol decrease by 10-20% during estrogen therapy (9, 10) . Increased concentrations of serum triglycerides (TG) are associated with an increased risk of CHD in women over the age of 50 (11) . According to the results of some studies, estrogen therapy may have unfavorable effects on serum TG levels (1, 12) . Furthermore, it has been suggested that the positive effect of postmenopausal HRT on serum lipids has a tendency to weaken or disappear over time (13) .
The effects of different estrogens and progestogens on concentrations of serum lipids have been widely examined, but there have been only a few truly longterm prospective population-based studies. Additionally, few investigators have assessed the effects of vitamin D 3 on serum lipids. Most studies have been carried out on animal models (14) (15) (16) or using large doses of vitamin D 3 exceeding the normal therapeutic range (14, 17) , and their results have been contradictory. Although vitamin D 3 supplementation is widely used in many countries to prevent postmenopausal osteoporosis, the effect of vitamin D 3 on the serum lipid profile remains poorly understood.
The aim of this prospective study was to determine the effects of sequential HRT and/or vitamin D 3 on the serum lipid profile in postmenopausal women. The serum lipoprotein concentrations were compared during the three-year follow-up to the baseline values and the factors which may also change the lipid profiles were excluded.
Materials and methods

Subjects and study design
Baseline In 1989 a postal inquiry was sent to all 14 200 47-to 56-year-old women in Kuopio Province, Eastern Finland, to investigate osteoporosis risk factors among perimenopausal women (18) . The population of the present study is a subgroup of the Kuopio Osteoporosis Risk Factor and Prevention Study population. The 464 postmenopausal women who were willing to undergo a five-year clinical trial were included in the study. The study inclusion criteria were the last menstrual period within 6-24 months prior to the study and no contraindications for HRT.
The participants were thereafter randomized in blocks of four into the following four treatment groups: (i) HRT group: estradiol valerate (2 mg) on cycle days 1-21, cyproterone acetate (1 mg) on cycle days 12-21 and a treatment-free interval on cycle days 21-28 (Climen, Schering Ltd, Berlin, Germany); (ii) Vit D 3 group: cholecalciferol (300 IU/day)+calcium lactate (500 mg/day, equivalent to 93 mg Ca ++ /day) (D-Calsor, Orion Corporation, Espoo, Finland), with no intake during June-August; (iii) HRT+Vit D 3 group: Climen and vitamin D 3 (as above); (iv) placebo group: calcium lactate (500 mg/day, equivalent to 93 mg Ca ++ /day) (Calcium Lactate, Rohto Ltd, Tampere, Finland).
The study design has been described previously in detail by Tuppurainen and colleagues (19) .
Briefly, in the baseline postal inquiry the daily consumption of milk products was ascertained. The daily calcium intake was calculated as the sum of calcium intake from milk, sour milk, yogurt (120 mg/dl) and cheese (87 mg/slice). This also estimates, indirectly, the intake of saturated fatty acids as milk products are the most important source of saturated fatty acids in the Finnish diet (20) . The monthly number of meals containing fish as the main course was recorded. Also, the weekly duration associated with physical activity was requested. If there was activity for at least three hours weekly, the subject was considered physically active. Additionally, the smoking and drinking habits were recorded by a standardized questionnaire. The duration of regular smoking and number of cigarettes consumed currently per day were registered, and the life-time amount of smoking was presented in packyears by dividing the life-time number of cigarettes by 20×365. The weekly consumption of alcohol was presented as absolute ethanol intake. The body weight was also requested in the baseline inquiry.
Written informed consent was obtained from the participants and the study design was approved by the Ethics Committee of the Kuopio University Hospital.
Follow-up
The patients were seen at the clinic after 12, 24 and 36 months of treatment. The visits were not performed during the summer months. Gynecological examination, palpation of the breasts, blood pressure measurement and standardized questions about compliance were performed. Fasting serum samples were taken during the same morning.
If the serum total cholesterol concentration was over 6.0 mmol/l at the baseline examination, dietary instructions were given after 6 months of therapy. If the serum total cholesterol concentration remained repeatedly over 7.0 mmol/l, a hypocholesterolemic medication was started. At the beginning of the study, 8 women had medication for hypercholesterolemia, and in 48 cases such medication was started during the follow-up period. All these 56 women who used guargum or other hypocholesterolemic medication were excluded from the final analysis. The excluded women were equally distributed in the treatment groups and their exclusion (data not shown) did not affect the conclusions.
The patients were weighed in light indoor clothing without shoes with electric scales at the 30 months follow-up visit.
Analyses
The concentrations of serum Chol, LDL-Chol, HDL-Chol and TG were measured in all groups before treatment and after 12, 24 and 36 months of treatment.
Concentrations of serum Chol and TG were measured enzymatically ((CHOD-PAP and GPO-PAP methods; Boehringer (Mannheim, Germany), using a Hitachi 717 analyzer (Tokyo, Japan)). The same cholesterol method was also used for HDL-Chol after removal of low density lipoprotein and very low density lipoprotein by dextran sulfate/MgCl 2 (21) . The concentration of serum LDL-Chol was calculated according to the formula published by Friedewald et al. (22) , in the form: LDLChol=Chol (HDL¹Chol+0.45 * TG).
The analytical variations of Chol, HDL-Chol and TG within series are 1.5%, 4% and 2% at the levels in question using the fully automated methods for Chol and TG, and are somewhat higher for the semiautomated measurement of HDL-Chol. The long-term variations of Chol, HDL-Chol and TG have been followed by measuring these analyses from quality control fresh samples of Labquality Ltd (Helsinki, Finland) from each survey and the between-series variations have been below 3%, 7% and 4.5% respectively. No drift in the analysed levels was found during the present study.
Statistical methods
The analyses were carried out on the basis of treatment. Statistical analyses of the longitudinal data were carried out using multivariate analysis of variance for repeated measures (MANOVA). Log transformation of lipid data was used as the lipid values were not normally distributed. Student's t-test for paired data was used to test significance of differences within groups if there was a time-related change within the group.
One-way analysis of variance with the Neuman-Keuls post hoc test was used to test the significance of differences between the baseline characteristics of the four groups and the differences between the relative LDL changes in the four groups. Because weights and body mass indexes (BMI) were not normally distributed after log transformation, one-way analysis of variance with the Kruskall-Wallis test was used to test differences in these parameters between the groups. The KruskallWallis test was also used to test differences between the groups in respect of other baseline data (diet, physical exercise and smoking).
A P value <0.05 was considered statistically significant. The results are reported as meansϮstandard error of mean (S.E.M.). All the data were analyzed using the SPSS program for UNIX (SPSS Inc., Chicago, IL, USA).
Results
During the three-year follow-up time a total of 76 women (16.4%) dropped out. In the hormone groups (HRT and HRT+Vit D 3 groups) there were 57 (24.6%) drop-outs with disorders of bleeding (n ¼ 12) and headache (n ¼ 11) as the most common reasons. Six women were excluded from the final analysis as a result of interruptions in HRT exceeding four months, all for non-medical reasons. Another six women were excluded because of missing laboratory data. In the non-hormone groups (Vit D 3 and placebo groups) 19 women (8.2%) dropped out, the most common reasons being climacteric symptoms (n ¼ 4) or other medical reasons to start HRT (n ¼ 5). As mentioned before, 56 subjects who used hypocholesterolemic medication were excluded from the final analysis.
A total of 320 women completed the three-year follow-up period. There were no statistically significant differences between the four groups in baseline characteristics (Table 1) . Body weight did not change significantly between the groups during the follow-up period ( Table 2) .
The concentrations of serum lipids and lipoproteins and the relative percentile changes (baseline¹follow-up value divided by baseline level, in percentage) of Chol, LDL-Chol, HDL-Chol, HDL/LDL ratio and TG are outlined according to treatment group in Tables 3-7 and Fig. 1 . There were no statistically significant differences between the four groups in the initial concentrations of serum total cholesterol, HDL-cholesterol, HDL/LDL ratio and triglycerides, but there was a significant difference (P<0.05) between the HRT group and the Vit D 3 group in the baseline concentration of serum LDL-cholesterol.
The concentration of serum total cholesterol decreased by 5.8% (P<0.001) in the HRT group and by 3.3% (P=0.023) in the HRT+Vit D 3 group, but no significant changes were observed in the other groups after three years. After two years, Chol increased by 4.5% (P=0.001) in the Vit D 3 group and by 2.3% (P=0.021) in the placebo group (Table 3) .
In the HRT group, serum concentrations of LDL-Chol decreased by 13 Using MANOVA, no significant differences were found between the groups with time but the above-mentioned time-related changes within the groups were statistically significant (P<0.001) ( Table 5) . At three years, the HDL/LDL ratio increased by 10.5% in the HRT group (P=0.006) and decreased by 10.5% in the Vit D 3 group (P<0.001) whereas no significant differences occurred in the HRT+Vit D 3 and the placebo groups. The differences between the HRT and the HRT+Vit D 3 groups were statistically significant (MANOVA, P=0.023) ( Table 6 ).
The serum concentrations of TG had increased significantly at three years in all four groups. The increase was 17.1% in the HRT group (P<0.001), 14.7% in the Vit D 3 group (P=0.014), 14.0% in the HRT+Vit D 3 group (P<0.001), and 18.8% in the placebo group (P<0.001). No significant differences were found between the groups (Table 7) .
Furthermore, we analyzed the relative changes in Chol, LDL-Chol, HDL-Chol and TG after three years and the results remained virtually identical (Fig. 1) . In oneway analysis of variance, there were significant differences (P<0.05) between the hormone and nonhormone groups in relative changes of Chol and LDLChol. Further, we adjusted the effects of baseline variables to the lipid responses by MANOVA (use of alcohol, smoking, physical activity) but these adjustments did not alter the results.
Discussion
The results of our study confirm the positive long-term effects of sequential estradiol valerate and cyproterone acetate treatment on serum total and LDL-Chol levels and suggest the long-term persistence of these effects. Additionally, we found that the serum concentrations of LDL-Chol increased and those of HDL-Chol and the HDL/LDL ratio decreased in the Vit D 3 group even more than those in the placebo group, although the differences between the groups were not statistically significant. Furthermore, the lipid changes regarding LDL-and HDL-Chol and their ratio in the HRT+Vit D 3 Table 3 The levels of serum total cholesterol (nmol/l) before and during the 1, 2 and 3 years of therapy in the four treatment groups. Values are means Ϯ S.E.M. group were less favorable than those in the pure hormone group. Our study population is unique due to the large number of subjects and the long follow-up time. The compliance was remarkably good with only 16.4% of the women dropping out during the three-year period. The computerized randomization to four treatment groups was successful as the basic characteristics of the four groups were comparable, allowing reliable interpretation of the results with the placebo group describing the natural course of lipoprotein levels after menopause.
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During treatment
The positive influence of estrogen monotherapy on the serum lipid profile has previously been well established. Oral estrogen therapy reduces serum total and LDL-cholesterol levels and increases HDL-cholesterol levels, but it may increase serum trigyceride levels (1, 2, 9).
In our study, the serum concentrations of Chol and LDL-Chol decreased in the HRT group after three years of treatment. Similar to the findings of Jensen et al. (23) , the results confirm that cyproterone acetate does not negate the positive effects of estrogen on LDL-Chol and Chol. Besides, our study showed the persistence of these favorable effects, in contrast to the results reported by Farish et al. (13) who, however, used a different progestin.
Serum concentrations of HDL-Chol did not change after two years but decreased significantly during the third year of therapy in the Vit D 3 , HRT+Vit D 3 and placebo groups. In previous studies, HDL-Chol has been reported to either decrease (24) or remain unchanged (25, 26) after the menopause. During HRT, even the combination of 17-hydroxyprogesterone to estrogen therapy has been reported to reverse the estrogeninduced increase in HDL-Chol (27, 28) . In our study, sequential estradiol valerate+cyproterone acetate had no influence on HDL-Chol. However, HRT inhibited the decreases in HDL-Chol that were observed in subjects taking vitamin D 3 supplementation or placebo.
Serum triglyceride concentrations increased in all groups. Menopause is associated with an 11-12% increase in serum TG concentrations (24, 29) . In addition, estrogen use has been reported to increase plasma triglyceride levels in postmenopausal women (7, 10) . However, the results of previous studies concerning the effects of estrogen-progestin treatment on triglyceride levels are controversial (7, 30) . In our study, triglyceride concentrations increased by 14.0-18.8% after three years. The trend was almost identical between the HRT and placebo groups, and between the Vit D 3 group and the HRT+Vit D 3 group. Our findings confirm the results of previous reports, showing that estrogen-progestin treatment does not increase the unfavorable effect of the menopause on serum triglyceride concentrations (7, 23) .
Pure vitamin D 3 medication led to a 4.1% increase in LDL-Chol and a 10.5% decrease in the HDL/LDL ratio. Addition of vitamin D 3 to estradiol valerate+cyproter-one acetate treatment decreased the positive effect of HRT on LDL-Chol while the serum concentrations of LDL-Chol and Chol decreased less in the HRT+Vit D 3 group than in the HRT group. Additionally, the HDL/ LDL ratio increased after three years by 10.5% in the Certain confounding factors may have influenced the results, although the successful randomization and the large number of subjects should weaken their impact. The groups were comparable in body weight and its changes. No evident differences were observed between the groups in dietary habits and level of physical activity. Our study population had relatively high calcium intake and the results must not be generalized to other populations with low calcium intake. The intake of saturated fat was not examined in detail but the major part of saturated fat in the Finnish diet comes from dairy products which were used in similar quantities in all groups.
One possible confounding factor was the lack of cyclic timing for the blood tests. The lipoprotein values may differ during the use of estrogen-progesterone from those obtained during the use of pure estrogen (33) . However, the large size of the study group and long follow-up period with repeated lipoprotein measurements minimized the possible confounding effects of cyclic variation of lipoproteins.
The effect of HRT on serum lipoprotein concentrations may be dependent on the pre-treatment serum lipid levels. From the final analyses in our study a relatively large number of hypercholesterolemic patients were excluded based on predetermined serum cholesterol levels and hypocholesterolemic medication during the follow up. This exclusion did not alter the results, but without other hypocholesterolemic medications these patients may have had a different lipid response to HRT.
The fact that initial LDL-Chol and total Chol concentrations were highest in the HRT group and lowest in the HRT+Vit D 3 group may also have had some influence on the results. However, according to the relative changes in lipoprotein concentrations, which takes into account the respective baseline value, the results remained consistent. Therefore our Table 6 The ratio of HDL-chol to LDL-chol (HDL/LDL ratio) before and during the 1, 2 and 3 years of therapy in the four treatment groups. Values are means Ϯ S.E.M. *P < 0:05 vs baseline value; **P < 0:01 vs baseline value; ***P < 0:001 vs baseline value (t-test for paired data). Table 7 The levels of serum triglycerides (mmol/l) before and during the 1, 2 and 3 years of therapy in the four treatment groups. Values are means Ϯ S.E.M. findings are not explained by the mild baseline variation in LDL-Chol and Chol. In terms of lipid metabolism, sequential treatment with estradiol valerate and cyproterone acetate is a safe combination. Its beneficial effect on the circulating concentrations of LDL-Chol and total Chol and lack of negative effect on HDL-Chol persist for at least three years. On the other hand, the effect of estradiol valerate+cyproterone acetate treatment was neutral with respect to triglyceride levels.
The long-term effects of HRT and vitamin D 3 need further examination, and the follow-up of our study group is continuing. The most interesting, but yet pathophysiologically unclear finding in our study was that vitamin D 3 seemed to affect serum lipid concentrations unfavorably and possibly counteracted positive lipid profile changes during estrogen replacement therapy. 
